COCRYSTAL PHARMA INC

Company Overview

Cocrystal Pharma is a clinical‑stage biotechnology company developing small‑molecule, direct‑acting antivirals against RNA viruses (influenza, coronaviruses, norovirus, HCV) using a structure‑based platform that combines X‑ray cocrystallography, computational and medicinal chemistry and enzymology. Lead programs include CC‑42344 (oral and inhaled PB2 influenza inhibitor in a Phase 2a human challenge study), CDI‑988 (oral pan‑viral 3CL protease inhibitor in Phase 1) and CC‑31244 (HCV N S5B inhibitor pursued for partnership). The company is very small (11 FTEs end of 2024) and relies heavily on CROs/CMOs, holds issued and pending patents, has had recent partnership changes (Merck termination) and faces significant regulatory, enrollment and financing risks given no product revenue and constrained liquidity.

Executive Compensation Practices

Given its clinical‑stage, pre‑revenue profile and constrained cash, executive pay is likely tilted toward equity‑based incentives (stock options/RSUs and milestone awards) with modest cash salaries and smaller cash bonuses than later‑stage peers. Compensation arrangements will typically link long‑term incentives to development and regulatory milestones (e.g., Phase 2/3 starts, positive toplines, licensing deals), and the company’s disclosures note that stock‑based compensation valuation (Black‑Scholes inputs such as volatility, term and forfeiture rates) materially affects reported expense—so grant timing and model assumptions are meaningful. Retention awards for key scientific leaders (given the small R&D team and high technical dependency) and one‑time grants tied to financings or partnership transactions are common; severance/change‑in‑control provisions may also be used to attract talent in the absence of high cash pay.

Insider Trading Considerations

Insider trading in a thinly‑traded, small biotech like Cocrystal is often driven by financing needs and milestone news: insiders historically tend to sell into equity raises or after positive public events, while purchases by insiders are relatively rare and strongly bullish signals. Watch Form 4 filings for sales around ATM/PIPE activity or shortly before announced financings—insider selling near financing announcements can presage dilution. Regulatory considerations include Section 16 short‑swing rules for officers/directors, typical blackout windows around clinical readouts and financings, and the use of 10b5‑1 plans; pay attention to disclosures and timing of option grants since valuation assumptions and grant timing can meaningfully affect reported compensation and signal management views of valuation.